company background image
OTLC

Oncotelic Therapeutics OTCPK:OTLC Stock Report

Last Price

US$0.05

Market Cap

US$19.4m

7D

-23.7%

1Y

-70.5%

Updated

04 Dec, 2022

Data

Company Financials +
OTLC fundamental analysis
Snowflake Score
Valuation2/6
Future Growth0/6
Past Performance3/6
Financial Health1/6
Dividends0/6

OTLC Stock Overview

Oncotelic Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in developing drugs for the treatment of orphan oncology indications.

Oncotelic Therapeutics, Inc. Competitors

Price History & Performance

Summary of all time highs, changes and price drops for Oncotelic Therapeutics
Historical stock prices
Current Share PriceUS$0.05
52 Week HighUS$0.26
52 Week LowUS$0.045
Beta-0.066
1 Month Change-14.48%
3 Month Change-38.39%
1 Year Change-70.48%
3 Year Change-75.81%
5 Year Changen/a
Change since IPO-54.91%

Recent News & Updates

Recent updates

Shareholder Returns

OTLCUS BiotechsUS Market
7D-23.7%4.2%1.5%
1Y-70.5%-7.4%-14.9%

Return vs Industry: OTLC underperformed the US Biotechs industry which returned -7.4% over the past year.

Return vs Market: OTLC underperformed the US Market which returned -14.9% over the past year.

Price Volatility

Is OTLC's price volatile compared to industry and market?
OTLC volatility
OTLC Average Weekly Movement21.8%
Biotechs Industry Average Movement11.2%
Market Average Movement7.4%
10% most volatile stocks in US Market15.7%
10% least volatile stocks in US Market3.3%

Stable Share Price: OTLC is more volatile than 90% of US stocks over the past 3 months, typically moving +/- 22% a week.

Volatility Over Time: OTLC's weekly volatility has increased from 15% to 22% over the past year.

About the Company

FoundedEmployeesCEOWebsite
n/a16Vuong Trieuhttps://www.oncotelic.com

Oncotelic Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in developing drugs for the treatment of orphan oncology indications. The company’s lead product candidate is OT-101, an antisense against TGF-ß2, which is in phase 3 clinical trials for pancreatic cancer and glioblastoma, as well as develops OT-101 for the treatment of various viruses, including severe acute respiratory syndrome and coronavirus. It also develops OXi4503 for the treatment of acute myeloid leukemia and myelodysplastic syndromes; and CA4P for the treatment of advanced metastatic melanoma.

Oncotelic Therapeutics, Inc. Fundamentals Summary

How do Oncotelic Therapeutics's earnings and revenue compare to its market cap?
OTLC fundamental statistics
Market CapUS$19.40m
Earnings (TTM)US$8.59m
Revenue (TTM)n/a

2.3x

P/E Ratio

0.0x

P/S Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report
OTLC income statement (TTM)
RevenueUS$0
Cost of RevenueUS$0
Gross ProfitUS$0
Other Expenses-US$8.59m
EarningsUS$8.59m

Last Reported Earnings

Sep 30, 2022

Next Earnings Date

n/a

Earnings per share (EPS)0.022
Gross Margin0.00%
Net Profit Margin0.00%
Debt/Equity Ratio42.0%

How did OTLC perform over the long term?

See historical performance and comparison